Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Queensland Health
Teva
Medtronic
US Department of Justice
Express Scripts
Chinese Patent Office
Accenture
McKesson
Julphar
Cerilliant

Generated: February 18, 2018

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 200243

« Back to Dashboard

NDA 200243 describes BUTALBITAL, ACETAMINOPHEN AND CAFFEINE, which is a drug marketed by Gilbert Labs, Graham Dm, Hikma Pharms, Mallinckrodt, Mayne Pharma Inc, Nexgen Pharma, Nuvo Pharm Inc, Tedor Pharma Inc, Mikart, Able, Actavis Labs Ut Inc, Cnty Line Pharms, Lannett Holdings Inc, Mirror Pharms Llc, Novast Labs Ltd, Specgx Llc, Sun Pharm Industries, Vintage Pharms, and Watson Labs, and is included in twenty-nine NDAs. It is available from forty-eight suppliers. Additional details are available on the BUTALBITAL, ACETAMINOPHEN AND CAFFEINE profile page.

The generic ingredient in BUTALBITAL, ACETAMINOPHEN AND CAFFEINE is acetaminophen; butalbital; caffeine. There are sixty-six drug master file entries for this compound. Forty-eight suppliers are listed for this compound. Additional details are available on the acetaminophen; butalbital; caffeine profile page.
Summary for 200243
Tradename:BUTALBITAL, ACETAMINOPHEN AND CAFFEINE
Applicant:Lannett Holdings Inc
Ingredient:acetaminophen; butalbital; caffeine
Patents:0
Formulation / Manufacturing:see details
Pharmacology for NDA: 200243
Suppliers and Packaging for NDA: 200243
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
BUTALBITAL, ACETAMINOPHEN AND CAFFEINE acetaminophen; butalbital; caffeine TABLET;ORAL 200243 ANDA Lannett Company, Inc. 0527-1695 N 0527-1695-01
BUTALBITAL, ACETAMINOPHEN AND CAFFEINE acetaminophen; butalbital; caffeine TABLET;ORAL 200243 ANDA Lannett Company, Inc. 0527-1695 N 0527-1695-05

Profile for product number 001

Active Rx/OTC/Discontinued:RXDosage:TABLET;ORALStrength325MG;50MG;40MG
Approval Date:Sep 13, 2012TE:AARLD:No

Complete Access Available with Subscription

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Daiichi Sankyo
Mallinckrodt
QuintilesIMS
Fuji
Boehringer Ingelheim
Federal Trade Commission
US Department of Justice
Deloitte
Citi

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot